CV Sciences (CVSI) Cash from Financing Activities (2011 - 2026)
CV Sciences (CVSI) posted Cash from Financing Activities of -$68000.0 for Q1 2026, down 126.36% sequentially from $258000.0 in Q4 2025, and down 114.17% YoY from $480000.0 in Q1 2025.
CV Sciences (CVSI) Cash from Financing Activities (2011 - 2026) Analysis & Trends
CV Sciences has reported Cash from Financing Activities for 16 years, with the latest figure at -$68000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 114.17% year-over-year to -$68000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$211000.0 (down 132.56% YoY) and the FY2025 annual result came in at $337000.0, up 953.12% from the prior year.
- Cash from Financing Activities retreated to -$68000.0 in Q1 2026 per CVSI's latest filing, from $258000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $1.4 million in Q1 2022 and troughed at -$872000.0 in Q1 2023.
- A 5-year average of $1823.5 and a median of -$87000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 2207.14% in 2024, down 498.21% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$738000.0 in 2022, then surged by 92.41% to -$56000.0 in 2023, then slumped by 498.21% to -$335000.0 in 2024, then soared by 177.01% to $258000.0 in 2025, then tumbled by 126.36% to -$68000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$68000.0, $258000.0, and -$234000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -54,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54,000.00 |
| Jun 30, 2026 | -54,000.00 |
| Mar 31, 2026 | -68,000.00 |
| Mar 31, 2026 | -68,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Sep 30, 2025 | -234,000.00 |
| Sep 30, 2025 | -234,000.00 |
| Jun 30, 2025 | -167,000.00 |
| Jun 30, 2025 | -167,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Dec 31, 2024 | -335,000.00 |
| Dec 31, 2024 | -335,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | -87,000.00 |
| Jun 30, 2024 | -87,000.00 |
| Mar 31, 2024 | -136,000.00 |
| Mar 31, 2024 | -136,000.00 |